Aspire-Lakewood Holdings, Inc.

AI-generated fair value estimate for this company.

Method: Option-value approach on the warrant's actual exercise terms: after two reverse stock splits (1-for-30 on 1/16/26, then 40-for-1 on 5/11/26), 1,200 ASBPW warrants are now required to purchase 1 ASBP common share at an aggregate exercise price of $13,800 (equivalent to the original $11.50/share strike scaled by the combined 1,200x split ratio); with ASBP last trading at $8.32/share, intrinsic value is $0 (the stock would need to rise roughly 1,650x to reach the effective strike), and even assuming a very high 150-200% implied volatility for this distressed micro-cap, Black-Scholes time value over the ~3.4 years to the Feb 18 2030 expiration is negligible, so per-warrant value is approximately $0.0005

Reasoning: Aspire Biopharma/Aspire-Lakewood Holdings is a serially reverse-split, going-concern-risk micro-cap (down ~98% over the trailing year); the warrant's strike was not economically adjusted in the holder's favor by the splits, making it a deep out-of-the-money option best valued by intrinsic-plus-negligible-time-value rather than a DCF of the underlying business